






















![]()
Q1: 2026-05-05 Earnings Summary
EPS of -$0.62 misses by $0.05
|
Revenue of
$58.59M
(-1.62% Y/Y)
beats by $10.95M
Schrödinger, Inc. (SDGR) Q1 2026 Earnings Call May 5, 2026 4:30 PM EDT
Company Participants
Jaren Madden - Chief Corporate Affairs Officer & Head of Investor Relations
Ramy Farid - CEO, President & Director
Richie Jain - Executive VP, CFO & Treasurer
Karen Akinsanya - President, Head of Therapeutics R&D and Chief Strategy Officer & Partnerships
Kenneth Lorton - Executive VP, CTO & COO of Software
Conference Call Participants
Steven Dechert - KeyBanc Capital Markets Inc., Research Division
Mani Foroohar - Leerink Partners LLC, Research Division
Brendan Smith - TD Cowen, Research Division
Michael Ryskin - BofA Securities, Research Division
Michael Yee - UBS Investment Bank, Research Division
Conor MacKay - BMO Capital Markets Equity Research
Matthew Hewitt - Craig-Hallum Capital Group LLC, Research Division
Presentation
Operator
Thank you for standing by. Welcome to Schrodinger's conference call to review First Quarter 2026 Financial Results. My name is Rob, and I'll be your operator for today's call. [Operator Instructions] Please be advised that this call is being recorded at the company's request.
Now I would like to introduce your host for today's conference, Ms. Jaren Madden, Chief Corporate Affairs Officer and Head of Investor Relations. Please go ahead.
Jaren Madden
Chief Corporate Affairs Officer & Head of Investor Relations
Thank you, and good afternoon, everyone. Welcome to today's call during which we will provide an update on the company and review our first quarter 2026 financial results. Earlier today, we issued a press release summarizing these results and progress across the company, which is available on our website at schrodinger.com.
During today's call, management will make statements that are forward-looking and made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including, without limitation, statements related to our outlook for the full year 2026, our plans to accelerate the growth of our software business and advance our therapeutics
此内容由惯性聚合(RSS阅读器)自动聚合整理,仅供阅读参考。 原文来自 — 版权归原作者所有。